Table 1.
Subj # | Age (Yr) | Gender | Race | MGFA Severity Class | MG-MMT | Thymectomy | MG Immunosuppressives | F1 | F3 | F4 | F5 |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 57 | Male | White | 1 | 6 | No | Pred 3.75 mg/d MMF 3000 mg/d | Y | Y | Y | Y |
2 | 75 | Female | White | 2A | 12 | No | Pred 10 mg/d MMF 1000 mg/d | Y | Y | Y | Y |
3 | 74 | Male | White | 2B | 15 | No | Pred 80 mg/d | Y | N | N | Y |
4 | 51 | Female | Black | 4A | 48 | No | none | Y | N | N | Y |
5 | 71 | Male | White | 2B | 2 | No | Pred 2.5 mg/d MMF 2500 mg/d | Y | N | N | Y |
6 | 67 | Male | White | 3B | 29 | No | none | Y | N | N | Y |
7 | 76 | Male | White | 3B | 18 | No | none | Y | Y | N | Y |
8 | 29 | Male | Black | 1 | 2 | No | Pred 10 mg/d AZA 200 mg/d | Y | N | N | Y |
9 | 48 | Female | White | 2B | 3 | No | AZA 350 mg/d | Y | N | N | Y |
10 | 61 | Female | White | 2A | 17 | No | Pred 15mg/d | N | N | N | Y |
11 | 81 | Male | White | 2A | 5 | No | MMF 2000 mg/d | Y | Y | N | Y |
12 | 77 | Male | White | 1 | 2 | No | Pred 2.5 mg/d | Y | N | N | Y |
13 | 76 | Female | White | 3B | 31 | No | none | Y | Y | N | Y |
14 | 36 | Female | Black | 2A | 8 | No | Pred 15 mg/d | Y | N | N | Y |
15 | 68 | Male | Black | 3A | 36 | Yes | TPEa | Y | Y | N | Y |
16 | 31 | Female | Asian | 3A | 18 | No | none | Y | Y | N | Y |
17 | 68 | Male | White | 2B | 5 | No | Pred 3 mg/d MMF 3000 mg/d | Y | Y | Y | Y |
18 | 47 | Male | Black | 4B | 13 | No | none | Y | Y | Y | Y |
19 | 80 | Male | White | 1 | 8 | No | MMF 1000 mg/d | Y | N | N | Y |
20 | 63 | Male | White | 2B | 14 | No | none | Y | Y | N | Y |
21 | 58 | Female | Black | 1 | 4 | Yes | AZA 200 mg/d | Y | Y | Y | Y |
22 | 73 | Female | White | 0 | 0 | No | MMF 2000 mg/d | Y | N | N | Y |
23 | 54 | Male | Black | 0 | 0 | Yes | MMF 1000 mg/d | Y | N | N | Y |
24 | 70 | Male | Black | 2B | 4 | No | none | Y | Y | N | Y |
25 | 72 | Female | White | 1 | 1 | No | MMF 2000 mg/d | Y | Y | Y | Y |
26 | 53 | Female | White | 2A | 12 | No | TPEa | N | N | N | Y |
27 | 48 | Male | White | 2B | 7 | No | none | Y | Y | N | Y |
28 | 79 | Female | White | 0 | 0 | No | MMF 2000 mg/d | Y | N | N | Y |
29 | 47 | Female | White | 2A | 12 | No | AZA 200 mg/d IVIga | Y | Y | Y | Y |
30 | 59 | Female | Black | 1 | 5 | Yes | AZA 200 mg/d | Y | Y | Y | Y |
31 | 66 | Female | White | 3A | 16 | No | RTXb MMF 2500 mg/d | Y | Y | Y | N |
32 | 66 | Male | White | 2B | 4 | Yes | None | Y | Y | N | N |
33 | 87 | Male | White | 1 | 3 | No | Pred 15 mg/d AZA 150 mg/d | Y | Y | N | N |
34 | 72 | Female | White | 0 | 2 | No | RTXa Pred 7.5 mg/d AZA 150 mg/d | Y | Y | N | N |
35 | 45 | Male | White | 3B | 14 | No | None | Y | Y | Y | Y |
36 | 71 | Male | White | 3B | 14 | No | none | Y | Y | Y | Y |
37 | 48 | Female | Black | 3A | 12 | Yes | AZA 200mg/d | Y | Y | Y | Y |
38 | 67 | Female | White | 3B | 21 | No | None | Y | Y | Y | Y |
39 | 65 | Male | White | 3B | 13 | No | None | Y | Y | N | Y |
40 | 61 | Male | White | 3B | 21 | No | None | Y | Y | Y | Y |
41 | 75 | Male | White | 3B | 14 | No | Pred 40 mg/d MMF 1000 mg/d | Y | Y | Y | Y |
42 | 67 | Female | White | 4A | 37 | No | Pred 20 mg/d | Y | Y | Y | Y |
43 | 61 | Male | White | 3A | 19 | No | None | Y | Y | Y | Y |
44 | 31 | Female | Black | 3A | 24 | Yes | None | Y | Y | Y | Y |
45 | 71 | Female | White | 3B | 13 | Yes | Pred 30 mg/d IVIga | Y | Y | Y | Y |
46 | 61 | Male | White | 3A | n/a | No | None | Y | Y | Y | Y |
47 | 86 | Female | White | 3B | 13 | No | Pred 60 mg/d TPEa | Y | Y | Y | Y |
48 | 77 | Male | White | 3B | 15 | No | MMF 500mg/d | Y | Y | Y | Y |
49 | 62 | Female | White | 3A | 24 | No | None | Y | Y | Y | Y |
Abbreviations: AZA=azathioprine; d=day; g=grams; MG=Myasthenia Gravis; mg=milligrams; MGFA=Myasthenia Gravis Foundation of America; MMF=mycophenolate mofetil; MG-MMT=myasthenia gravis manual muscle testing score at time of blood draw; n/a= not available; Pred=prednisone; RTX=rituximab, TPE=therapeutic plasma exchange.
Within 90 days of blood draw
Within 12 months of blood draw